HRP20161284T1 - METODE LIJEČENJA MULTIPLOG MIJELOMA KORIŠTENJEM KOMBINIRANIH TERAPIJA TEMELJENIH NA HuLuc63 S BORTEZOMIBOM - Google Patents
METODE LIJEČENJA MULTIPLOG MIJELOMA KORIŠTENJEM KOMBINIRANIH TERAPIJA TEMELJENIH NA HuLuc63 S BORTEZOMIBOM Download PDFInfo
- Publication number
- HRP20161284T1 HRP20161284T1 HRP20161284TT HRP20161284T HRP20161284T1 HR P20161284 T1 HRP20161284 T1 HR P20161284T1 HR P20161284T T HRP20161284T T HR P20161284TT HR P20161284 T HRP20161284 T HR P20161284T HR P20161284 T1 HRP20161284 T1 HR P20161284T1
- Authority
- HR
- Croatia
- Prior art keywords
- huluc63
- administered
- bortezomib
- use according
- dose
- Prior art date
Links
- 229960004137 elotuzumab Drugs 0.000 title claims 31
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 title claims 18
- 229960001467 bortezomib Drugs 0.000 title claims 18
- 208000034578 Multiple myelomas Diseases 0.000 title claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 title claims 3
- 238000002648 combination therapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000001990 intravenous administration Methods 0.000 claims 16
- 238000001802 infusion Methods 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Claims (23)
1. Upotreba HuLuc63 u pripravi lijeka, spomenuti HuLuc63 kao humanizirano antitijelo IgG1 ima varijabilno područje teškog lanca koje odgovara sekvenci SEQ ID NO:5 i varijabilno područje lakog lanca koje odgovara sekvenci SEQ ID NO:6; za liječenje multiplog mijeloma ljudskog pacijenta, gdje se HuLuc63 primijenjuje u kombinaciji s bortezomibom i gdje se HuLuc63 daje kao intravenozna infuzija u dozi od 2.5 mg/kg do20 mg/kg, a bortezomib se treba primijeniti kao intravenozna infuzija u dozi od 0.2 mg/m2 do 2.0 mg/m2.
2. Uporaba prema zahtjevu 1, naznačen time što se bortezomib primijenjuje intravenoznom dozom od 1,0 mg/m2 do 1.3 mg/m2.
3. Upotreba prema zahtjevu 1, naznačen time što se bortezomib primijenjuje intravenoznom dozom od 1,0 mg/m2.
4. Uporaba prema zahtjevu 1, naznačen time što se bortezomib primijenjuje intravenoznom dozom od 1,3 mg/m2.
5. Uporaba prema bilo kojem od zahtjeva 1-4, naznačen time da se HuLuc63 primjenjuje intravenoznom dozom od 2,5 mg/kg.
6. Uporaba prema bilo kojem od zahtjeva 1-4, naznačen time da se HuLuc63 primjenjuje intravenoznom dozom od 5 mg/kg.
7. Uporaba prema bilo kojem od zahtjeva 1-4, naznačen time da se HuLuc63 primjenjuje intravenoznom dozom od 10 mg/kg.
8. Uporaba u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačen time da pacijent prima HuLuc63 jednom svakih 10 dana.
9. Uporaba prema bilo kojem od zahtjeva 1-8, naznačen time da pacijent prima bortezomib četiri puta u tri tjedna ciklusa.
10. Uporaba prema zahtjevu 9, naznačen time da se bortezomib daje na dane 1, 4, 8 i 11, nakon čega slijedi razdoblje od 10 dana mirovanja.
11. Uporaba u skladu s bilo kojim od patentnih zahtjeva 1-10, naznačen time dase HuLuc63 i bortezomib koriste s trećim lijekom koji sadrži deksametazon.
12. HuLuc63, spomenuti HuLuc63 kao humanizirano antitijelo IgG1 ima varijabilno područje teškog lanca koje odgovara sekvenci SEQ ID NO:5 i varijabilno područje lakog lanca koje odgovara sekvenci SEQ ID NO:6; za uporabu u liječenju multiplog mijeloma ljudskog pacijenta, naznačen time da se HuLuc63 primjenjuje u kombinaciji s bortezomibom i gdje se HuLuc63 daje kao intravenozna infuzija u dozi od 2.5 mg/kg do 20 mg/kg, a bortezomib se daje kao intravenozna infuzija u dozi od 0.2 mg/ m2 do 2.0 mg/m2.
13. HuLuc63 za upotrebu prema patentnom zahtjevu 12, naznačen time, da je HuLuc63 pružen u prvom farmaceutskom pripravku, a bortezomib je pružen u drugom farmaceutskom pripravku.
14. HuLuc63 za uporabu u skladu s patentnim zahtjevom 12 ili 13, naznačen time da se bortezomib primjenjuje intravenoznom dozom od 1,0 mg/m2 do 1.3 mg/m2.
15. HuLuc63 za uporabu u skladu s patentnim zahtjevom 12 ili 13, naznačen time da se bortezomib primjenjuje intravenoznom dozom od 1,0 mg/m2.
16. HuLuc63 za uporabu u skladu s patentnim zahtjevom 12 ili 13, naznačen time da se bortezomib primjenjuje intravenoznom dozom od 1.3 mg/m2.
17. HuLuc63 za uporabu u skladu s bilo kojim od patentnih zahtjeva 12-16, naznačen time da se HuLuc63 primjenjuje intravenoznom dozom od 2,5 mg/kg.
18. HuLuc63 za uporabu u skladu s bilo kojim od patentnih zahtjeva 12-16, naznačen time da se HuLuc63 primjenjuje intravenoznom dozom od 5 mg/kg.
19. HuLuc63 za uporabu u skladu s bilo kojim od patentnih zahtjeva 12-16, naznačen time da se HuLuc63 primjenjuje intravenoznom dozom od 10 mg/kg.
20. HuLuc63 za uporabu u skladu s bilo kojim od patentnih zahtjeva 12-19, naznačen time da pacijent primi HuLuc63 jednom u svakih 10 dana.
21. HuLuc63 za uporabu u skladu s bilo kojim od patentnih zahtjeva 12-20, naznačen time da pacijent prima bortezomib četiri puta u tri tjedna ciklusa.
22. HuLuc63 za uporabu prema zahtjevu 21, naznačen time da se bortezomib daje na dane 1, 4, 8 i 11 nakon čega slijedi razdoblje od 10 dana mirovanja.
23. HuLuc63 za uporabu u skladu s bilo kojim od patentnih zahtjeva 12-22, naznačen time, da se HuLuc63 i bortezomib koriste s trećim lijekom koji sadrži deksametazon.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83618506P | 2006-08-07 | 2006-08-07 | |
US94426207P | 2007-06-15 | 2007-06-15 | |
PCT/US2007/075403 WO2008019378A1 (en) | 2006-08-07 | 2007-08-07 | Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20161284T1 true HRP20161284T1 (hr) | 2016-12-16 |
Family
ID=38831279
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150449TT HRP20150449T1 (en) | 2006-08-07 | 2015-04-27 | Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies |
HRP20161284TT HRP20161284T1 (hr) | 2006-08-07 | 2016-10-06 | METODE LIJEČENJA MULTIPLOG MIJELOMA KORIŠTENJEM KOMBINIRANIH TERAPIJA TEMELJENIH NA HuLuc63 S BORTEZOMIBOM |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150449TT HRP20150449T1 (en) | 2006-08-07 | 2015-04-27 | Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies |
Country Status (24)
Country | Link |
---|---|
US (4) | US8632772B2 (hr) |
EP (5) | EP2641601B8 (hr) |
JP (1) | JP5340935B2 (hr) |
CN (1) | CN101686971B (hr) |
AU (1) | AU2007281684C1 (hr) |
BR (1) | BRPI0716647A2 (hr) |
CA (1) | CA2660356C (hr) |
CY (5) | CY1116247T1 (hr) |
DK (2) | DK2068874T3 (hr) |
ES (2) | ES2589302T3 (hr) |
HK (1) | HK1129853A1 (hr) |
HR (2) | HRP20150449T1 (hr) |
HU (4) | HUE029027T2 (hr) |
IL (2) | IL196919A (hr) |
LT (4) | LT2641601T (hr) |
LU (3) | LU93276I2 (hr) |
MX (1) | MX2009001441A (hr) |
NL (1) | NL300840I2 (hr) |
NO (1) | NO346835B1 (hr) |
NZ (1) | NZ574978A (hr) |
PL (2) | PL2068874T3 (hr) |
PT (2) | PT2068874E (hr) |
SI (2) | SI2068874T1 (hr) |
WO (1) | WO2008019378A1 (hr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5340935B2 (ja) | 2006-08-07 | 2013-11-13 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | 抗cs1抗体に基づく組合せ療法を用いて多発性骨髄腫を処置する方法 |
PT2068930E (pt) | 2006-08-07 | 2012-10-23 | Abbott Biotherapeutics Corp | Composições e métodos utilizando anticorpos anti-cs1 para tratar mieloma múltiplo |
JP2011523560A (ja) * | 2008-06-02 | 2011-08-18 | ダナ−ファーバー キャンサー インスティテュート インク. | Xbp1ペプチド、cd138ペプチドおよびcs1ペプチド |
BRPI0914789A2 (pt) * | 2008-06-16 | 2015-10-20 | Immunogen Inc | efeitos sinérgicos |
BRPI0919668A2 (pt) * | 2008-10-21 | 2018-05-29 | Onyx Therapeutics, Inc. | terapia de combinação com epóxi-cetonas de peptídeo |
AU2010293383B2 (en) | 2009-09-10 | 2014-12-18 | Kyowa Kirin Co., Ltd. | Medicament including antibody composition specifically bound to human CC chemokine receptor 4 (CCR4) |
JP2013512195A (ja) * | 2009-11-24 | 2013-04-11 | セルジーン コーポレイション | ビタミンd耐性腫瘍細胞においてビタミンd感受性を回復させるための免疫調節性化合物 |
CN102241773B (zh) * | 2010-05-13 | 2014-05-14 | 四川大学 | 抗骨髓瘤细胞多克隆抗体及其制备方法 |
AU2013337247B2 (en) | 2012-11-05 | 2018-08-09 | Dana-Farber Cancer Institute, Inc. | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions |
US20160264670A1 (en) | 2013-11-06 | 2016-09-15 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
WO2015069785A1 (en) * | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma |
EP3783020A1 (en) * | 2013-11-21 | 2021-02-24 | F. Hoffmann-La Roche AG | Anti-alpha-synuclein antibodies and methods of use |
EA201790439A1 (ru) * | 2014-08-22 | 2017-07-31 | Селджин Корпорейшн | Способы лечения множественной миеломы с применением иммуномодулирующих соединений в комбинации с антителами |
WO2016049022A1 (en) * | 2014-09-23 | 2016-03-31 | Board Of Trustees Of Michigan State University | Compositions and methods for modulating an immune response |
WO2016054354A1 (en) | 2014-10-02 | 2016-04-07 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating malignancies |
US10011657B2 (en) | 2014-10-31 | 2018-07-03 | Abbvie Biotherapeutics Inc. | Anti-CS1 antibodies and antibody drug conjugates |
US10302644B2 (en) | 2014-11-04 | 2019-05-28 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating multiple myeloma |
JP2017537927A (ja) * | 2014-12-04 | 2017-12-21 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | がん(骨髄腫)を処置するための抗cs1および抗pd1抗体の併用 |
PT3294769T (pt) | 2015-05-13 | 2021-04-13 | Morphosys Ag | Tratamento para mieloma múltiplo (mm) |
PT3313528T (pt) * | 2015-06-29 | 2021-09-16 | Bristol Myers Squibb Co | Regimes de dosagem imunoterapêuticos compreendendo pomalidomida e um anticorpo anti-cs1 para tratamento do cancro |
CN105688185B (zh) * | 2016-03-13 | 2019-03-19 | 浙江药苑生物科技有限公司 | 一种用于治疗骨髓增生、骨癌的药物组合物及其用途 |
SG11201907923VA (en) | 2017-03-29 | 2019-09-27 | Agency Science Tech & Res | Anti oligosaccharide antibody |
EP3714257A4 (en) * | 2017-11-22 | 2021-08-11 | Hillstream Biopharma Inc. | POLYMERIC NANOPARTICLE WITH BORTEZOMIB |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
EP4055392A1 (en) | 2019-11-05 | 2022-09-14 | Bristol-Myers Squibb Company | M-protein assays and uses thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL112969A (en) | 1994-03-17 | 2001-05-20 | Baxter Int | Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator |
DE69633668T2 (de) | 1995-05-25 | 2006-03-09 | Shimon Slavin | Allogene zelltherapie für krebs infolge allogener stammzellen transplantation |
CN103393681B (zh) * | 2002-05-17 | 2017-04-12 | 细胞基因公司 | 用于治疗和控制多发性骨髓瘤的方法及组合物 |
US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
CA2595398A1 (en) * | 2004-11-04 | 2006-05-11 | Fibron Limited | Treatment of b-cell malignancies |
US20080095768A1 (en) | 2006-08-07 | 2008-04-24 | Pdl Biopharma, Inc. | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
PT2068930E (pt) | 2006-08-07 | 2012-10-23 | Abbott Biotherapeutics Corp | Composições e métodos utilizando anticorpos anti-cs1 para tratar mieloma múltiplo |
JP5340935B2 (ja) | 2006-08-07 | 2013-11-13 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | 抗cs1抗体に基づく組合せ療法を用いて多発性骨髄腫を処置する方法 |
-
2007
- 2007-08-07 JP JP2009523968A patent/JP5340935B2/ja active Active
- 2007-08-07 ES ES13168383.1T patent/ES2589302T3/es active Active
- 2007-08-07 BR BRPI0716647A patent/BRPI0716647A2/pt not_active Application Discontinuation
- 2007-08-07 ES ES07840746.7T patent/ES2535437T3/es active Active
- 2007-08-07 US US11/835,257 patent/US8632772B2/en active Active
- 2007-08-07 EP EP13168383.1A patent/EP2641601B8/en active Active
- 2007-08-07 EP EP13168364.1A patent/EP2641600A1/en not_active Withdrawn
- 2007-08-07 AU AU2007281684A patent/AU2007281684C1/en active Active
- 2007-08-07 EP EP16169025.0A patent/EP3115049A1/en not_active Withdrawn
- 2007-08-07 CN CN200780033988XA patent/CN101686971B/zh active Active
- 2007-08-07 EP EP07840746.7A patent/EP2068874B1/en active Active
- 2007-08-07 PT PT78407467T patent/PT2068874E/pt unknown
- 2007-08-07 EP EP15152731.4A patent/EP2942057A1/en not_active Withdrawn
- 2007-08-07 WO PCT/US2007/075403 patent/WO2008019378A1/en active Application Filing
- 2007-08-07 DK DK07840746T patent/DK2068874T3/da active
- 2007-08-07 HU HUE13168383A patent/HUE029027T2/en unknown
- 2007-08-07 PL PL07840746T patent/PL2068874T3/pl unknown
- 2007-08-07 CA CA2660356A patent/CA2660356C/en active Active
- 2007-08-07 NZ NZ574978A patent/NZ574978A/xx unknown
- 2007-08-07 NO NO20090968A patent/NO346835B1/no unknown
- 2007-08-07 SI SI200731641T patent/SI2068874T1/sl unknown
- 2007-08-07 MX MX2009001441A patent/MX2009001441A/es active IP Right Grant
- 2007-08-07 PT PT131683831T patent/PT2641601T/pt unknown
- 2007-08-07 SI SI200731803A patent/SI2641601T1/sl unknown
- 2007-08-07 DK DK13168383.1T patent/DK2641601T3/en active
- 2007-08-07 PL PL13168383T patent/PL2641601T3/pl unknown
- 2007-08-07 LT LTEP13168383.1T patent/LT2641601T/lt unknown
-
2009
- 2009-02-05 IL IL196919A patent/IL196919A/en active Protection Beyond IP Right Term
- 2009-10-23 HK HK09109870.7A patent/HK1129853A1/xx unknown
-
2013
- 2013-12-23 US US14/139,096 patent/US20140322201A1/en not_active Abandoned
-
2015
- 2015-04-24 CY CY20151100379T patent/CY1116247T1/el unknown
- 2015-04-27 HR HRP20150449TT patent/HRP20150449T1/hr unknown
- 2015-08-24 US US14/834,077 patent/US20160137735A1/en not_active Abandoned
-
2016
- 2016-02-03 IL IL243933A patent/IL243933A0/en unknown
- 2016-08-18 CY CY20161100817T patent/CY1117992T1/el unknown
- 2016-10-06 HR HRP20161284TT patent/HRP20161284T1/hr unknown
- 2016-10-20 HU HUS1600045C patent/HUS1600045I1/hu unknown
- 2016-10-20 HU HUS1600044C patent/HUS1600044I1/hu unknown
- 2016-10-20 HU HUS1600043C patent/HUS1600043I1/hu unknown
- 2016-10-24 LU LU93276C patent/LU93276I2/fr unknown
- 2016-10-24 LU LU93275C patent/LU93275I2/fr unknown
- 2016-10-24 LU LU93277C patent/LU93277I2/fr unknown
- 2016-10-25 NL NL300840C patent/NL300840I2/nl unknown
- 2016-10-26 CY CY2016036C patent/CY2016036I1/el unknown
- 2016-10-26 CY CY2016038C patent/CY2016038I1/el unknown
- 2016-10-26 CY CY2016037C patent/CY2016037I1/el unknown
- 2016-10-27 LT LTPA2016031C patent/LTC2068874I2/lt unknown
- 2016-10-27 LT LTPA2016030C patent/LTPA2016030I1/lt unknown
- 2016-10-27 LT LTPA2016029C patent/LTPA2016029I1/lt unknown
-
2017
- 2017-08-07 US US15/670,681 patent/US20170342150A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20161284T1 (hr) | METODE LIJEČENJA MULTIPLOG MIJELOMA KORIŠTENJEM KOMBINIRANIH TERAPIJA TEMELJENIH NA HuLuc63 S BORTEZOMIBOM | |
HRP20191162T1 (hr) | Postupci liječenja ankilozantnog spondilitisa uporabom anti-il-17 protutijela | |
HRP20171939T1 (hr) | Formulacija protutijela i režimi terapije | |
RU2434640C2 (ru) | Лечение метастатического рака молочной железы | |
HRP20150400T1 (hr) | Lijeäśenje pedijatrijske akutne limfoblastiäśne leukemije | |
HRP20110198T1 (hr) | Indikacija doziranja progesterona u liječenju traumatske ozljede mozga | |
JP2009518441A5 (hr) | ||
EA201891154A1 (ru) | Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей | |
RS53905B1 (en) | METHODS AND TREATMENTS FOR TUMOR DISEASE | |
JP2009519257A5 (hr) | ||
NZ625391A (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
JP2014169326A5 (hr) | ||
AR099078A2 (es) | Un medicamento que comprende acetato de glatiramer | |
JP2012102122A5 (hr) | ||
JP2016514132A5 (hr) | ||
IL309340A (en) | Dosing regimen for missing doses of paliperidone long-acting injectable esters | |
RU2014127298A (ru) | Применения иммуноконъюгатов, мишенью которых является cd138 | |
Stieglbauer et al. | Beneficial effect of rituximab monotherapy in multifocal motor neuropathy | |
JP2014513722A5 (hr) | ||
HRP20201632T1 (hr) | Režimi doziranja melflufena kod raka | |
JP2019521156A5 (hr) | ||
RU2015112121A (ru) | Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний | |
RS54658B1 (en) | TREATMENT OF MULTIPLE SCLEROSIS (MS) WITH KAMPAT-1 H | |
JP2009538916A5 (hr) | ||
US9687518B2 (en) | Medicament for treating muscle and skeletal diseases |